Novo Plunges as Investors Seek More Robust Sales Targets
Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports. (Source: Bloomberg)
READ NEXT
More on the wire
FROM THE PUBLISHER
A major cryptocurrency super PAC, Fairshake, plans to spend $30 million in Ohio opposing former Sen. Sherrod Brown’s (D) bid to return to the Senate, the group has confirmed to The Hill. Brown, who spent nearly two decades representing the Buckeye State before being ousted in 2024, is facing off against incumbent Sen. Jon Husted...
FROM THE PUBLISHER
There’s a red-sauce-fueled resurgence happening in Little Italy.
FROM THE PUBLISHER
Vice President Vance, who has long cast himself as a champion of free speech, defended President Trump’s ban on three outlets from the White House on Monday, calling the move “totally appropriate.” “He’s not banning media outlets. What he’s doing is saying ‘we’re not going to give you special access to the White House if...